Skip to content

Dossier · SG · Dormant

SG · Sweetgreen, Inc. · Stock research

Last analysed ·

Current thesis

Cyclospora outbreak crushed SG from ~$9 to $6.15 (Jul 16) on guilt by association; FDA traceback cleared it Jul 17 (source: Taylor Farms iceberg at Taco Bell), sparking an 18% bounce to ~$7.08. Now below the $7.92–$8.43 consensus with 24.5% of float short but comps still guided −4% to −2% and Aug 6 Q2 is the binary. Relief rally, not narrative acceleration.

Invalidation trigger

A weekly close below $6.15 takes out the outbreak-panic floor and confirms the July 17 clearing rally failed, fully round-tripping the June recovery leg. Secondarily, Q2 comps on 2026-08-06 worse than the guided ~−4% or restaurant-level margin under 14.2% breaks the turnaround sequencing.

Thesis status

Open commitment catalyst in 18dscored if the trigger above fires How this is scored →

Latest analysis and events for SG —

As of 2026-07-19, orbyd's latest analysis for Sweetgreen, Inc. (SG): Cyclospora outbreak crushed SG from ~$9 to $6.15 (Jul 16) on guilt by association; FDA traceback cleared it Jul 17 (source: Taylor Farms iceberg at Taco Bell), sparking an 18% bounce to ~$7.08. Now below the $7.92–$8.43 consensus with 24.5% of float short but comps still guided −4% to −2% and Aug 6 Q2 is the binary. Relief rally, not narrative acceleration.

Invalidation trigger: A weekly close below $6.15 takes out the outbreak-panic floor and confirms the July 17 clearing rally failed, fully round-tripping the June recovery leg. Secondarily, Q2 comps on 2026-08-06 worse than the guided ~−4% or restaurant-level margin under 14.2% breaks the turnaround sequencing.

Next dated event on file: — catalyst in 18d.

Current Thesis

The June recovery leg round-tripped, and it did so for a reason that had nothing to do with Sweetgreen. Shares slid from ~$9.07 (June 26) to an intraday $6.15 on July 16 roughly a third of the market cap as a multistate Cyclospora outbreak put every leafy-green concept under suspicion. On July 17 the FDA traceback converged on a single supplier, Taylor Farms de Mexico, and a single vector: shredded iceberg lettuce served at Taco Bell across Indiana, Kentucky, Michigan, Ohio and West Virginia. SG was never implicated. The stock gapped and ran as much as 21% intraday, its largest single-day gain since August 2024, closing the week near $7.08–$7.38.

That leaves a name trading below the $7.92–$8.43 consensus target cluster for the first time since May, with 24.53% of float sold short and a binary print on August 6. The setup is cleaner on price than it was at $9 in June. What has not changed is the P&L: Q1 comps −12.8%, traffic −11.2%, an adjusted −$0.27/sh loss, and full-year guidance calling for same-store sales of −4% to −2% against $1–6M of adjusted EBITDA. A relief rally off a disproven accusation is not a narrative accelerating; it is a discount closing.

Bullish and bearish views on Sweetgreen, Inc.

The model's bull view on Sweetgreen, Inc. (SG), in brief: Exogenous shock resolved: FDA traceback (July 17) identified Taylor Farms de Mexico iceberg lettuce at Taco Bell as the outbreak source 1,644 cases, 94 hospitalizations, illness onsets May 13–July 13. The bear view: Four straight earnings misses and three quarters of falling revenue. Both cases follow in full.

Bull Case

  • Exogenous shock resolved: FDA traceback (July 17) identified Taylor Farms de Mexico iceberg lettuce at Taco Bell as the outbreak source 1,644 cases, 94 hospitalizations, illness onsets May 13–July 13. Sweetgreen was cleared by exclusion, and the stock recovered ~18% in one session.
  • Short interest rebuilt into the panic: 22.889M shares short, 24.53% of float, 5.78 days to cover. The March-to-June compression from 27% to 20% reversed during the scare, restoring squeeze fuel ahead of the August 6 print.
  • Bank of America raised its target from $7.50 to $8.90 on July 17, citing improving restaurant-level margins and cost discipline. Oppenheimer moved $9 → $10.
  • Point72 disclosed 6.2% (6,622,017 shares, Schedule 13G, May 15) and insiders bought ~$3.4M with zero sales following the May 8 Q1 report.
  • Price now sits below the analyst midpoint $7.08 against a $7.92–$8.43 consensus (13 analysts, Hold, range $5.60–$15) inverting the poor risk/reward that defined the June-quarter high.
  • Cheap on sales at ~1.25x price-to-sales on $674.69M trailing revenue, versus CAVA above 8x and Chipotle above 3x.

Bear Case

  • Four straight earnings misses and three quarters of falling revenue. Q1 revenue fell 2.9% YoY to $161.5M. Consensus for Q2 is $191.8M, up 3.9% a sharp deceleration from the 21.1% posted in the year-ago quarter.
  • Guidance still describes contraction. Full-year same-store sales of −4% to −2% and adjusted EBITDA of $1–6M means an entire year at roughly breakeven.
  • The sector overhang has not closed. Taylor Farms expanded its voluntary iceberg recall to 27 states on July 18, and the supplier also serves McDonald's, Chipotle, Walmart, Target, Costco and Kroger. Leafy-green demand can stay impaired even for chains that were never implicated.
  • Sweetgreen's own SEC risk disclosures name cyclospora specifically and concede that fresh in-restaurant preparation carries greater contamination exposure than commissary-based competitors. The next outbreak is a live tail risk, not a hypothetical.
  • roughly 41% of the reported stake is optionality that can expire rather than committed equity. Reading the 13G as a hard institutional floor overstates it.
  • Citi cut its target from $10 to $9. Consensus has been drifting down, and the $15 high target is a lone outlier against a cluster near $8.
  • Beta near 2.16 with 62 daily moves greater than 5% in the past year. Position sizing has to respect that this name gaps.

Setup & Price Structure

Price ~$7.08 (July 18), up 5.4% year-to-date and 55–58% below the $16.26–$16.70 52-week high set in July 2025. The structure is a failed recovery followed by a violent event reversal. May produced a stacked sentiment melt-up: +5% (May 14), +17% on the Point72 13G (May 15), +11% on JPMorgan's Overweight and $13 target (May 22), peaking near $9.63. That faded to $7.42 (June 5), rebuilt to ~$9.07 (June 26), then broke hard through the whole base into $6.15 (July 16).

The $7.40 shelf that defined the early-June higher low was lost decisively during the outbreak selloff, which means the June recovery leg is technically finished regardless of the July 17 rebound. Price is now rebuilding from beneath it. The relevant levels are $6.15 as the panic floor and the $7.40–$7.45 zone as first overhead resistance the July 17 high stalled almost exactly at the broken shelf, which is where a genuine reclaim would have to prove itself on volume. Above that, the $9.00–$9.63 region caps twice.

Market cap $841M. Trailing P/E of ~50 is meaningless here Q1 GAAP earnings were inflated by a one-time Spyce divestiture gain while operations lost $0.27/sh.

Catalyst Calendar (next 30 days)

  • 2026-08-06 (confirmed, announced 2026-07-08) Q2 2026 results after market close, webcast 2:00pm PT / 5:00pm ET. Consensus revenue $191.8M (+3.9% YoY), adjusted EPS −$0.05. The number that matters is same-store sales against the roughly −4% guided, improving from Q1's −12.8%, plus restaurant-level margin against the 14.2%–14.7% guide.
  • Ongoing through late July CDC and FDA Cyclospora investigation updates. Taylor Farms recall expanded to 27 states on July 18; further expansion or a second implicated supplier would re-pressure the whole leafy-green complex.
  • ~Late July (est.) Cyclospora incubation runs 1–2 weeks, so illness onsets reported through late July still reflect pre-recall exposure. Case counts rising after the recall would signal an uncontained source.
  • ~Mid-August (est.) Q2 13F filings disclose whether Point72 and other holders added, held or exited through the July drawdown.

What Would Change Our Mind

A weekly close below $6.15 takes out the outbreak-panic floor and says the July 17 clearing news failed to hold at that point the June recovery has fully round-tripped and the name is back to being cheap for cause. Conversely, a decisive reclaim of $7.45 on above-average volume would put the broken June shelf back overhead as support and re-open the case.

On fundamentals, the August 6 print resolves it in one direction or the other. Comps worse than the guided −4%, or restaurant-level margin below 14.2%, breaks the turnaround sequencing and makes the full-year $1–6M EBITDA guide unreachable. Comps inflecting toward flat with margin holding above 14.5% would validate the wraps rollout and the April traffic step-up management flagged on the May 8 call, and would do so with a quarter of float sold short.

The honest framing for a fresh entry today: this is a discounted event name into a binary, not a narrative worth chasing. Entering ahead of August 6 is a coin-flip on a company still guiding to negative comps. Waiting for the print costs some upside and removes the gap risk in a stock that moves 5%-plus 62 times a year.

Correlation Notes

  • Tracks fast-casual peers CAVA, CMG, WING and SHAK, but with roughly 2x the beta. It leads them down on sector fear and lags them up on sector strength.
  • New and specific since July 2026: SG now carries direct correlation to food-safety headlines across the entire leafy-green supply chain, including outbreaks at unrelated chains. The July 16 drawdown was pure guilt by association an exposure that reprices on news the company does not control.
  • Taylor Farms is a shared industry chokepoint. Its customer list spans McDonald's, Chipotle, Walmart, Target, Costco and Kroger, so supplier-level failures transmit across restaurant and grocery names simultaneously.
  • Hedge-fund crowding via the Point72 position cuts both ways. Concentrated ownership in a $841M-cap name with 24.53% short interest produces moves in both directions that are disconnected from operating results.
  • Correlated to consumer-discretionary rotation and rate expectations as a high-beta, unprofitable, long-duration equity it trades like a small-cap growth proxy, not like a defensive restaurant.
  • Input-cost sensitivity is live: the June 22 USDA crop-cost forecast, with fertilizer up as much as 13% alongside higher fuel and electricity, drove a 6.6% single-day decline and bears directly on the restaurant-margin guide.

Notes

  • Q2 2026 earnings: 2026-08-06 after close the real binary; comps vs Q1's −12.8% is the tell. Blackout avoid if approaching with a fresh entry.
  • EPS 'beats' are noise here Q1 $1.05 was a one-time Spyce divestiture gain, not operations. Track adj EBITDA (FY guide $1–6M) and comps, NOT headline EPS.
  • Street target cluster $4.50–$9.00 (avg $6.74); JPM $13 is the lone bull. Stock already trades above consensus fair value poor R:R for fresh longs.
  • Value-trap watch: cheap + a bounce ≠ accelerating narrative. Only chase on a >$11–12 breakout WITH comps confirmation; otherwise this is dead money until Aug 6.
  • Theme engine tags this ACCELERATING via the cyclical-rebound bucket, but the SG-specific narrative is MATURING/faded post the 2026-05-22 upgrade pop.
  • Q2 2026 earnings: 2026-08-06 after close the real binary. Comps vs the guided ~−4% (improvement from Q1's −12.8%) is the tell. Earnings-blackout risk if approaching with a fresh entry.
  • May +45% pop has round-tripped: faded from ~$9.63 (05-22) to $7.42 (06-05), below the $8 level the prior dossier flagged. Momentum leg failed confirms the faded-momentum/value-trap read.
  • May spike was a stacked sentiment event: +5% (05-14), +17% on Point72's 6.2% 13G disclosure (05-15), +11% on JPM Overweight $13 (05-22). Hedge-fund crowding cuts both ways 13F/13G unwind risk.
  • EPS headlines are noise: Q1 GAAP was inflated by a one-time Spyce divestiture gain; operations posted an adjusted −$0.27/sh loss. Track adj EBITDA (FY guide $1–6M) and comps, NOT headline EPS.
  • Street: 13–15 analysts Hold, avg PT ~$7.8 (range $5–$13). TD Cowen Hold, PT $8 (05-27). JPM $13 is the lone bull. Price now trades through consensus single-digit upside to fair value.
  • Value-trap watch: only chase on a >$11–12 breakout WITH Q2 comp confirmation, or a reclaim of the ~$9.50 May shelf on volume. Otherwise dead money until 08-06.
  • 52-week range updated to $4.49–$16.70 (was $16.26 high). Current $7.42 ≈ −55% off the high, +65% off the low; high beta ~2.16.
  • Q2 2026 earnings 2026-08-06 after close the real binary; comps vs guided ~−4% (Q1 was −12.8%) and restaurant margin vs the 14.2–14.7% guide are the tells. Earnings-blackout risk if approaching with a fresh entry.
  • Track adj EBITDA (FY guide $1–6M) and comps, NOT headline EPS Q1 GAAP was distorted by a one-time Spyce divestiture gain; operations posted a −$0.27/sh adjusted loss.
  • Stock trades ABOVE consensus: 15 analysts Hold, avg PT ~$7.81, range $5–$13; most houses ~$7, JPM $13 the lone bull. Negative single-digit upside to fair value at ~$9 poor R:R for fresh longs.
  • Squeeze/sponsorship support: short interest 27%→20% of float since March, ~$3.4M insider buys with zero sales post-Q1, Point72 6.2% 13G (~May 15). Watch for short-interest rebuild and 13F/13G unwind.
  • Correction to prior 'round-tripped / dead-money' read: the May pop did NOT fully round-trip; SG re-accelerated through June (+~60% 3mo, ~+100% off March lows) and reclaimed most of the May range. Momentum revived; only the fundamentals lag.
  • June 22 USDA crop-cost forecast (fertilizer +13%, fuel/electricity up) is a recurring margin headwind into a 14.2–14.7% restaurant-margin guide; the −6.6% reaction shows real input-cost sensitivity.
  • Value-trap watch: cheap on 1.6x P/S vs CAVA 8.3x / CMG 3.4x does not equal accelerating fundamentals. Chase only on a >$9.63 — reclaim on volume WITH comp confirmation, or a clean higher-low re-test; otherwise stand aside until Aug 6.
  • Q2 2026 earnings CONFIRMED 2026-08-06 after close (announced 2026-07-08), webcast 5:00pm ET. Consensus rev $191.8M (+3.9% YoY), adj EPS -$0.05. Earnings-blackout risk on any fresh entry from ~2026-08-01.
  • Archetype moved 4 -> 5: over the next 30 days the Aug 6 print is the single dominant variable. The turnaround framing is intact longer-term but the near-term distribution is binary.
  • The $7.40 early-June higher low was LOST decisively on the July outbreak selloff. Prior dossier's invalidation level was breached the June recovery leg is technically finished. New floor reference is the $6.15 panic low (2026-07-16); $7.40-$7.45 is now overhead resistance, and the Jul 17 rally stalled right at it.
  • SG was NEVER implicated in the Cyclospora outbreak. FDA traceback (2026-07-17) pinned it on Taylor Farms de Mexico shredded iceberg served at Taco Bell 1,644 cases, 94 hospitalizations, 5 states. SG fell ~32% on pure guilt by association, then +18.49% on the clearing.
  • Taylor Farms recall EXPANDED to 27 states on 2026-07-18 and the supplier also serves McDonald's, Chipotle, Walmart, Target, Costco, Kroger. Sector overhang is not closed watch for a second implicated supplier or rising post-recall case counts (1-2 week incubation means late-July onsets still reflect pre-recall exposure).
  • Do not read the 13G as a hard committed-equity floor that optionality can expire.
  • Short interest RE-EXPANDED during the scare: 22.889M sh, 24.53% of float, 5.78 days to cover. The March-June compression from 27% -> 20% reversed. Squeeze fuel is restored into the Aug 6 print.
  • EPS headlines remain noise. Q1 GAAP was inflated by a one-time Spyce divestiture gain; operations posted an adjusted -$0.27/sh loss. Trailing P/E ~50 is meaningless. Track adj EBITDA (FY guide $1-6M), comps, and restaurant-level margin (guide 14.2-14.7%).
  • SG's own SEC risk disclosures name cyclospora specifically and concede fresh in-restaurant prep carries higher contamination exposure than commissary-based rivals. Recurrence is a live structural tail risk, not a one-off.
  • Analyst drift as of mid-July: BofA $7.50 -> $8.90 (07-17), Oppenheimer $9 -> $10, Citi $10 -> $9. Consensus Hold, avg PT ~$7.92-$8.43, range $5.60-$15. Price finally trades BELOW the target cluster the inverse of the June setup.
  • High-beta mechanics: beta ~2.16, 62 daily moves >5% in the trailing year, market cap only $841M. Size to gap risk, not to conviction in the story.
  • Value-trap discipline still applies: cheap plus a bounce is not an accelerating narrative. A reclaim of $7.45 on above-average volume, or comps confirmation on Aug 6, is what would restore the recovery leg.

Related · shared themes

MTUM

The AI-memory leg MTUM rotated into at the May reconstitution has rolled over: SOX -20%+ from its June peak, memory names in a bear market, and the fund closed $302.09 on 2026-07-17, below the $310 shelf that defined the post-reconstitution base. With ~36% in the semi complex and no rebalance until November, this is a falling-knife AI-hardware proxy with a lagged exit.

LOW

WEST

Westrock Coffee Company

Conway extract/RTD platform inflecting capex to cash: Q1 (5/07) beat revenue with record adjusted EBITDA, FCF-positive-H2 guide reaffirmed, and a 6/30 debt-maturity extension cleared the near-term refi wall. Stock re-rated ~the published invalidation level→$9.50 near the $9.81 high on PT hikes real and accelerating, but a fresh entry above the ~$8.88 average PT into an ~8-week gap to Q2 (~8/6) is extended.

LOW

WTI

W&T Offshore, Inc.

The Iran-war crude premium has fully unwound: WTI crude ~$69 (Jul 2) vs $100+ in May after the June 17 US–Iran MOU reopened Hormuz, and W&T which never rallied on the spike has broken its $4 shelf to $3.11 (Jul 1). A hedged, earnings-rolling non-participant; the geopolitical theme is dead. Fresh capital stays out.

LOW

ALGT

Allegiant Travel Company

A three-week sell-side upgrade cascade (Goldman $125→$142, JPM initiates OW $156, Citi/Melius Buy $156–$160, Barclays OW $145) plus a fuel-cost tailwind as the Hormuz crude spike unwinds has re-rated Allegiant's post-Sunseeker ULCC turnaround. Theme is accelerating with the whole airline complex (JETS at pre-Covid highs), but the move has more than doubled off the low into a seasonally soft Q2 print on ~2026-08-03.

HIGH

See also · stocks to watch